Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo

European Journal of Pharmacology

Volumn 636, Issue 1-3, 2010, Pages 189-197

  Zrieki, Afraa ^a   Farinotti, Robert ^a,b   Buyse, Marion ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Caco 2; Colitis; COX 2 inhibitor; MDR1; P gp; TNBS

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLYCOPROTEIN P; INDOMETACIN HEPTYL ESTER; NIMESULIDE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CELL STRAIN CACO 2; COLITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENTERITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; CACO-2 CELLS; COLITIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENZYME INDUCTION; HUMANS; INDOMETHACIN; INFLAMMATION; MALE; MICE; P-GLYCOPROTEIN; TRINITROBENZENESULFONIC ACID; UP-REGULATION;

EID: 77952672440     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.039     Document Type: Article

References (54)

1. Agoff S.N., Brentnall T.A., Crispin D.A., Taylor S.L., Raaka S., Haggitt R.C., Reed M.W., Afonina I.A., Rabinovitch P.S., Stevens A.C., Feng Z., Bronner M.P. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 2000, 157:737-745.
2. Bonner G.F. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am. J. Gastroenterol. 2001, 96:1306-1308.
3. Bonner G.F., Walczak M., Kitchen L., Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2000, 95:1946-1948.
4. Borst P., Schinkel A.H., Smit J.J., Wagenaar E., Van Deemter L., Smith A.J., Eijdems E.W., Baas F., Zaman G.J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther. 1993, 60:289-299.
5. Buchman A.L., Paine M.F., Wallin A., Ludington S.S. A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig. Dis. Sci. 2005, 50:2312-2315.
6. Dudhgaonkar S.P., Tandan S.K., Kumar D., Raviprakash V., Kataria M. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacology 2007, 15:188-195.
7. El Miedany Y., Youssef S., Ahmed I., El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 2006, 101:311-317.
8. Evans J.M., McMahon A.D., Murray F.E., McDevitt D.G., MacDonald T.M. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619-622.
9. Fakhoury M., Lecordier J., Medard Y., Peuchmaur M., Jacqz-Agrain E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. Inflamm. Bowel. Dis. 2006, 12:745-749.
10. Fardel O., Lecureur V., Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 1996, 27:1283-1291.
11. Farmer R.G., Easley K.A., Rankin G.B. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig. Dis. Sci. 1993, 38:1137-1146.
12. Farrell R.J., Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 2003, 178:339-346.
13. Farrell R.J., Murphy A., Long A., Donnelly S., Cherikuri A., O'Toole D., Mahmud N., Keeling P.W., Weir D.G., Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000, 118:279-288.
14. Farrell R.J., Menconi M.J., Keates A.C., Kelly C.P. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment. Pharmacol. Ther. 2002, 16:1021-1031.
15. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
16. Fontaine M., Elmquist W.F., Miller D.W. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life. Sci. 1996, 59:1521-1531.
17. Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 1996, 118:1841-1847.
18. Iizasa H., Genda N., Kitano T., Tomita M., Nishihara K., Hayashi M., Nakamura K., Kobayashi S., Nakashima E. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. J. Pharm. Sci. 2003, 92:569-576.
19. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
20. Kessel D., Beck W.T., Kukuruga D., Schulz V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res. 1991, 51:4665-4670.
21. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87:1344-1350.
22. Langmann T., Moehle C., Mauerer R., Scharl M., Liebisch G., Zahn A., Stremmel W., Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004, 127:26-40.
23. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997, 272:3406-3410.
24. Mahadevan U., Loftus E.V., Tremaine W.J., Sandborn W.J. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 2002, 97:910-914.
25. Martin A.R., Villegas I., La Casa C., Alarcon de la Lastra C. The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur. J. Pharmacol. 2003, 481:281-291.
26. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
27. Munkholm P., Langholz E., Hollander D., Thornberg K., Orholm M., Katz K.D., Binder V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994, 35:68-72.
28. O'Banion M.K., Winn V.D., Young D.A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4888-4892.
29. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS. Lett. 1993, 330:156-160.
30. Patel V.A., Dunn M.J., Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 2002, 277:38915-38920.
31. Pellequer Y., Weissenborn V., Lamprecht A. Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis. J. Pharm. Sci. 2007, 96:2145-2153.
32. Puhlmann U., Ziemann C., Ruedell G., Vorwerk H., Schaefer D., Langebrake C., Schuermann P., Creutzig U., Reinhardt D. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. 2005, 312:346-354.
33. Raab Y., Sundberg C., Hallgren R., Knutson L., Gerdin B. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am. J. Gastroenterol. 1995, 90:614-620.
34. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Taddei G.L. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int. J. Gynecol. Cancer 2005, 15:255-260.
35. Ratnasinghe D., Daschner P.J., Anver M.R., Kasprzak B.H., Taylor P.R., Yeh G.C., Tangrea J.A. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?. Anticancer Res. 2001, 21:2141-2147.
36. Saitoh H., Hatakeyama M., Eguchi O., Oda M., Takada M. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 1998, 87:73-75.
37. Sambuelli A.M., Negreira S.M., Gil A.H., Huernos S.P., Goncalves S., Toro M.A., Kogan Z., Cabanne A., Camarero S., Bai J.C., Lazarowski A.J. Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis. Acta. Gastroenterol. Latinoam. 2006, 36:23-32.
38. Singer I.I., Kawka D.W., Schloemann S., Tessner T., Riehl T., Stenson W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998, 115:297-306.
39. Storch C.H., Ehehalt R., Haefeli W.E., Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 2007, 323:257-264.
40. Stratton M.D., Sexe R., Peterson B., Kaminski D.L., Li A.P., Longo W.E. The effect of trinitrobenzene sulfonic acid (TNB) on colonocyte arachidonic acid metabolism. J. Surg. Res. 1996, 60:375-378.
41. Surowiak P., Pawelczyk K., Maciejczyk A., Pudelko M., Kolodziej J., Zabel M., Murawa D., Drag M., Gansukh T., Dietel M., Lage H. Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res. 2008, 28:2967-2974.
42. Takeuchi K., Smale S., Premchand P., Maiden L., Sherwood R., Thjodleifsson B., Bjornsson E., Bjarnason I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2006, 4:196-202.
43. Tanaka K., Suemasu S., Ishihara T., Tasaka Y., Arai Y., Mizushima T. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur. J. Pharmacol. 2009, 603:120-132.
44. te Velde A.A., de Kort F., Sterrenburg E., Pronk I., ten Kate F.J., Hommes D.W., van Deventer S.J. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm. Bowel. Dis. 2007, 13:325-330.
45. Thorn M., Finnstrom N., Lundgren S., Rane A., Loof L. Expression of cytochrome P450 and MDR1 in patients with proctitis. Ups. J. Med. Sci. 2007, 112:303-312.
46. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 1992, 267:24248-24252.
47. Wirtz S., Neurath M.F. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int. J. Colorectal. Dis. 2000, 15:144-160.
48. Yacyshyn B., Maksymowych W., Bowen-Yacyshyn M.B. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Hum. Immunol. 1999, 60:677-687.
49. Yu L., Wu W.K., Li Z.J., Liu Q.C., Li H.T., Wu Y.C., Cho C.H. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonami de (SC236) via inhibiting P-glycoprotein activity. Mol. Pharmacol. 2009, 75:1364-1373.
50. Zatelli M.C., Luchin A., Piccin D., Tagliati F., Bottoni A., Vignali C., Bondanelli M., degli Uberti, E.C. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 2005, 90:5754-5760.
51. Zatelli M.C., Luchin A., Tagliati F., Leoni S., Piccin D., Bondanelli M., Rossi R., degli Uberti, E.C. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer 2007, 14:1029-1038.
52. Zhang L., Lu Y.M., Dong X.Y. Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin. J. Dig. Dis. 2004, 5:110-114.
53. Zibell G., Unkruer B., Pekcec A., Hartz A.M., Bauer B., Miller D.S., Potschka H. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.
54. Zrieki A., Farinotti R., Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 2008, 25:1991-2001.